RemeGen Co., Ltd. (OTCMKTS:REGMF – Get Free Report) saw a significant growth in short interest in May. As of May 29th, there was short interest totaling 1,131,607 shares, a growth of 67.8% from the May 14th total of 674,500 shares. Based on an average trading volume of 0 shares, the short-interest ratio is presently ? days.
RemeGen Stock Performance
Shares of RemeGen stock remained flat at $9.50 during midday trading on Tuesday. RemeGen has a twelve month low of $9.50 and a twelve month high of $15.91. The firm’s 50-day moving average is $11.20 and its two-hundred day moving average is $10.56.
About RemeGen
RemeGen Co, Ltd. is a Shanghai-based biopharmaceutical company focused on the research, development and commercialization of innovative antibody-based therapeutics for oncology and immunology. Since its founding in 2009, RemeGen has built a portfolio of antibody–drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies aimed at addressing a range of solid tumors and immune-related conditions. The company leverages its in-house discovery, engineering and manufacturing capabilities to advance its pipeline from preclinical stages through clinical trials.
RemeGen’s lead product candidate, Disitamab Vedotin (RC48), is a HER2-targeting ADC that has received regulatory approval in China for HER2-positive gastric cancer and urothelial carcinoma.
Featured Articles
- Five stocks we like better than RemeGen
- Goldman’s S&P 500 Target Looks More Reachable After the Latest Rally
- 3 Stocks Diluting Shareholders to Fund Big Long-Term Opportunities
- Father’s Day Investing: 3 Stocks Built for Long-Term Returns
- This Golden Cross Could Send Urban Outfitters to New Highs
Receive News & Ratings for RemeGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RemeGen and related companies with MarketBeat.com's FREE daily email newsletter.
